US$ 23.85
semaglutide with medicaid Michigan cuts off weight-loss drugs for most patients, saving $240M Increases but pronounced state-level disparities
Description
In this post, well break down and debunk some of the most common myths about these treatments using clinical data, professional insights, and practical experience

In 2023, these products generated sales of USD 18.4 billion, and the total GLP-1 market is projected to grow to USD 120 billion by 2030, according to Global Data
What a smart, non-surgical GLP-1 laxity plan looks like Most patients get the best outcome when treatment is staged, not rushed

GIP may have a role in -/-cell crosstalk

But for those who are overweight or obese, or those with diabetes, the science seems very favorable.
At Renew Health & Wellness, we offer semaglutide as part of a medically guided weight loss approach designed to address these underlying challenges